scispace - formally typeset
A

Andrew Watson

Researcher at Bristol-Myers Squibb

Publications -  40
Citations -  2409

Andrew Watson is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Ruthenium & Borrowing hydrogen. The author has an hindex of 21, co-authored 40 publications receiving 2262 citations. Previous affiliations of Andrew Watson include Seattle Biomed & University of Bath.

Papers
More filters
Journal ArticleDOI

Ruthenium-catalyzed N-alkylation of amines and sulfonamides using borrowing hydrogen methodology.

TL;DR: The alkylation of amines by alcohols has been achieved using 0.5 mol % [Ru(p-cymene)Cl(2)](2) with the bidentate phosphines dppf or DPEphos as the catalyst.
Journal ArticleDOI

Plasma viremia in macaques infected with simian immunodeficiency virus : plasma viral load early in infection predicts survival

TL;DR: Findings are consistent with the available clinical data concerning viral load correlates early in HIV infection, and they provide further support for the view that disease outcome in lentiviral infection may be largely determined by events that occur shortly after infection.
Journal ArticleDOI

Ruthenium-Catalyzed Oxidation of Alcohols into Amides

TL;DR: The synthesis of secondary amides from primary alcohols and amines has been developed using commercially available [Ru(p-cymene)Cl(2)](2) with bis(diphenylphosphino)butane (dppb) as the catalyst.
Journal ArticleDOI

Borrowing Hydrogen Methodology for Amine Synthesis under Solvent-Free Microwave Conditions

TL;DR: Application of microwave heating to the Borrowing Hydrogen strategy to form C-N bonds from alcohols and amines is presented, removing the need for solvent and reducing the reaction times while still yielding results comparable with those using thermal heating.
Journal ArticleDOI

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

TL;DR: It is hypothesize that SIVIG reduced the spread of virus by eliminating or reducing plasma virus through immune complexes during the first four to 8 weeks of infection and then maintaining this low level of viremia until the host immune response was capable of virus control.